TSND-201 for Post Traumatic Stress Disorder

An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (EMPOWER-1)

Recruiting Phase 3 Interventional Study
Post Traumatic Stress Disorder
Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
300 (estimated)
Sponsor
Transcend Therapeutics · Industry
Who this trial is looking for

This trial is looking for adults with PTSD to test a new treatment called TSND-201. Participants will receive TSND-201 or a placebo once a week for 4 weeks, followed by an 8-week follow-up.

Are You a Good Fit for This Trial?

You may be able to join if

  • I have been diagnosed with PTSD for at least 6 months.
  • I have tried at least one treatment for PTSD.
  • I can communicate well to complete interviews and questionnaires.
  • I do not have any other significant health issues.

You may not be able to join if

  • I have a primary diagnosis of another mental health disorder.
  • My body mass index (BMI) is below 18 or above 40.
  • I cannot stop using nicotine for at least 8 hours.
  • I am taking medications or therapies that are not allowed.
  • I have a history of significant heart or brain problems.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This study is evaluating the safety and efficacy of TSND-201 in adults with PTSD. Eligible participants will enter a 4-week Treatment Period where they will be randomized 1:1:1 to receive one of two doses of TSND-201 or placebo, once per week. Following the Treatment Period, participants will enter an 8-week Follow-up Period.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Meets the DSM-5 criteria for current PTSD diagnosis, with a symptom duration of at least 6 months. * Tried at least one pharmacological treatment for PTSD or trauma-focused psychotherapy. * Proficient in communication (verbal and reading) to complete interviews and written que…
Contacts

Study Director

650-769-6472

amanda@transcendtherapeutics.com

CONTACT